Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8772656 | 0.98 | FDPS (0.49) | FDPSALDH1A1MAPK1MEN1THRB | |
| SCHEMBL9122728 | 0.98 | FDPS (0.49) | FDPSALDH1A1MAPK1MEN1THRB | |
| SCHEMBL7829405 | 0.98 | FDPS (0.49) | FDPSALDH1A1MAPK1MEN1THRB | |
| SCHEMBL7462928 | 0.95 | FDPS (0.51) | FDPSALDH1A1MAPK1TSHRMEN1 | |
| SCHEMBL8615157 | 0.91 | FDPS (0.54) | FDPSALDH1A1MAPK1TSHRCYP1A2 | |
| SCHEMBL6739941 | 0.91 | FDPS (0.54) | FDPSALDH1A1MAPK1TSHRCYP1A2 | |
| SCHEMBL1200827 | 0.90 | FDPS (0.45) | FDPSALDH1A1MEN1THRBKMT2A | |
| SCHEMBL7466433 | 0.90 | FDPS (0.53) | FDPSALDH1A1MAPK1TSHRMEN1 | |
| SCHEMBL3841589 | 0.90 | S1PR2 (0.52) | FDPSALDH1A1MAPK1MEN1THRB | |
| SCHEMBL8772739 | 0.89 | HTR1A (0.50) | FDPSALDH1A1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2013-05-23 | — | — | US | disclosed |
| EP-2576514-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT SA (FR) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011151423-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151423-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2011-12-08 | — | — | WO | disclosed |
| EP-1032572-B1 | PYRANONES, METHOD FOR THE PRODUCTION AND USE THEREOF | SCHWABE WILLMAR GMBH & CO (DE) | 2002-12-11 | — | — | EP | disclosed |
| EP-0882030-B1 | 2,1,3-BENZOTHIA(OXA)DIAZOLE DERIVATIVES HAVING AN ENDOTHELIN RECEPTOR ANTAGONISTIC EFFECT | MERCK PATENT GMBH (DE) | 2001-09-12 | — | — | EP | disclosed |
| US-6017916-A | Nonpeptide endothelin antagonists I | WARNER-LAMBERT COMPANY (US) | 2000-01-25 | — | — | US | disclosed |
| US-6017939-A | 2,1,3-benzothia(OXA)diazole derivatives having an endothelin receptor antagonistic effect | MERCK PATENT GESELLSCHAFT (DE) | 2000-01-25 | — | — | US | disclosed |
| WO-1998042702-A1 | ENDOTHELIN-RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 1998-10-01 | — | — | WO | disclosed |
| US-5691373-A | TREATING SUBARACHNOID HEMORRHAGE | WARNER-LAMBERT COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | TUBB3, TUBB, TUBB1 | FDPS 1240/4885ALDH1A1 2257/4885MAPK1 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.